Trivium Point Advisory LLC Purchases 67,293 Shares of Pfizer Inc. $PFE

Trivium Point Advisory LLC lifted its position in shares of Pfizer Inc. (NYSE:PFE) by 182.0% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 104,266 shares of the biopharmaceutical company’s stock after purchasing an additional 67,293 shares during the period. Trivium Point Advisory LLC’s holdings in Pfizer were worth $2,657,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of the business. Norges Bank purchased a new stake in Pfizer in the 2nd quarter worth approximately $2,270,157,000. Vanguard Group Inc. increased its stake in shares of Pfizer by 1.9% during the second quarter. Vanguard Group Inc. now owns 533,363,457 shares of the biopharmaceutical company’s stock valued at $12,928,730,000 after buying an additional 10,198,330 shares during the period. Arrowstreet Capital Limited Partnership raised its holdings in shares of Pfizer by 43.4% during the second quarter. Arrowstreet Capital Limited Partnership now owns 18,718,955 shares of the biopharmaceutical company’s stock valued at $453,747,000 after acquiring an additional 5,662,309 shares in the last quarter. Assenagon Asset Management S.A. lifted its stake in Pfizer by 75.0% in the third quarter. Assenagon Asset Management S.A. now owns 8,689,103 shares of the biopharmaceutical company’s stock worth $221,398,000 after acquiring an additional 3,722,531 shares during the period. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its holdings in Pfizer by 84.9% in the second quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 7,561,946 shares of the biopharmaceutical company’s stock valued at $183,302,000 after acquiring an additional 3,472,240 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer launched a Phase 2 study of an mRNA influenza vaccine, advancing its mRNA platform into a large seasonal market — a successful program could drive multi-year upside and higher-margin sales. Pfizer Advances mRNA Flu Vaccine Pipeline With New Phase 2 Trial
• Positive Sentiment: Pfizer updated a Phase 1 study for a new obesity injectable — progress in obesity therapeutics targets a very large market and would materially diversify revenue if clinical development continues to advance. Pfizer Quietly Advances New Obesity Shot With Fresh Phase 1 Study Update
• Positive Sentiment: The FDA granted full approval to Pfizer’s BRAFTOVI regimen for first‑line treatment of BRAF V600E-mutant metastatic colorectal cancer (mCRC), converting prior accelerated approval — this expands the label and reduces regulatory risk, supporting near‑term oncology sales. Pfizer Secures Full FDA Approval for BRAFTOVI as First-Line Treatment in mCRC
• Positive Sentiment: Income-focused narratives are supporting demand: coverage and write-ups highlighting Pfizer’s attractive dividend (yield cited >6% by some outlets) are drawing investor interest into the stock as a yield play. Love Dividends? 1 Stock to Buy Now With a Yield Over 6%
• Neutral Sentiment: Analysts at Zacks moved Pfizer from “strong sell” to “hold,” which reduces immediate downside narrative but is not a strong buy signal. Zacks upgrade to Hold
• Neutral Sentiment: Recent quarterly results beat EPS and revenue estimates, showing operating resilience despite slight year‑over‑year revenue decline — supports the stock’s valuation but doesn’t eliminate structural concerns.
• Negative Sentiment: RBC Capital initiated coverage with an Underperform and $25 target, warning of a projected $15B–$20B structural revenue decline through 2030 — this report injects a bearish, long‑term revenue risk narrative that can cap upside. RBC Initiates with $25 Target

Wall Street Analysts Forecast Growth

Several research analysts have commented on the stock. Guggenheim restated a “buy” rating on shares of Pfizer in a report on Wednesday, December 17th. Wolfe Research set a $24.00 price target on shares of Pfizer and gave the company an “underperform” rating in a research report on Wednesday, December 17th. Sanford C. Bernstein reissued a “market perform” rating and issued a $30.00 price target on shares of Pfizer in a research note on Friday, October 31st. Scotiabank assumed coverage on shares of Pfizer in a report on Thursday, November 13th. They issued a “sector outperform” rating and a $30.00 price objective for the company. Finally, Citigroup assumed coverage on Pfizer in a report on Tuesday, December 2nd. They set a “neutral” rating and a $26.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have given a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat.com, Pfizer has a consensus rating of “Hold” and a consensus target price of $27.70.

Pfizer Price Performance

PFE stock opened at $27.61 on Friday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.97 and a current ratio of 1.28. The firm has a 50 day moving average price of $26.13 and a 200-day moving average price of $25.41. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $27.94. The firm has a market capitalization of $156.97 billion, a price-to-earnings ratio of 20.30 and a beta of 0.47.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, beating analysts’ consensus estimates of $0.57 by $0.09. Pfizer had a return on equity of 20.25% and a net margin of 12.42%.The company had revenue of $17.56 billion during the quarter, compared to analyst estimates of $16.93 billion. During the same quarter last year, the company earned $0.63 EPS. The firm’s revenue for the quarter was down 1.2% on a year-over-year basis. Equities research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 23rd will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 6.2%. The ex-dividend date of this dividend is Friday, January 23rd. Pfizer’s payout ratio is currently 126.47%.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.